Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Director · CEO | July 06, 2021 | July 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TENAX THERAPEUTICS, INC.
Report date July 06, 2021 · Filed July 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2031-07-06 | Direct | 50,000 |
Reported balance
After 2021-07-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-06 · Grant · Acquired 50,000 · Balance 50,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2021 Filed Jul 9, 2021 00:06 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001654954-21-007767 · section16.xml · derivative · entry 1 DiTonno Anthony A · CIK 0001395876 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-06 Read SEC document |
| January 05, 2021 Filed Jan 12, 2021 22:02 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.85 | $0.00 |
DisclosureSEC source: 0001654954-21-000348 · section16.xml · derivative · entry 1 DiTonno Anthony A · CIK 0001395876 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common stock · 90,000 shares Expires 2031-01-05 Read SEC document |
| March 01, 2020 Filed May 15, 2020 21:00 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001654954-20-005663 · section16.xml · derivative · entry 1 DiTonno Anthony A · CIK 0001395876 · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-03-01 Read SEC document |
| June 01, 2018 Filed Apr 22, 2019 20:30 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.10 | $0.00 |
DisclosureSEC source: 0001654954-19-004651 · section16.xml · derivative · entry 1 DiTonno Anthony A · CIK 0001395876 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: common stock · 50,000 shares Expires 2028-06-01 F1 · derivative.exercise_date: Vests as to 25% of the award on each anniversary of the grant date. Read SEC document |
| May 01, 2018 Filed Apr 18, 2019 20:31 UTC | TENAX THERAPEUTICS, INC. TENX · Entity 979 | GrantStock Option (right to buy) · Derivative | 500 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001654954-19-004582 · section16.xml · derivative · entry 1 DiTonno Anthony A · CIK 0001395876 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2028-05-01 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.